Profile: Strongbridge Biopharma plc (SBBP.OQ)
24 May 2019
Strongbridge Biopharma plc, incorporated on May 26, 2015, is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis, a neuromuscular disorder. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS.
The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole) and COR-005 (veldoreotide). The Company's product candidate, COR-003, is a cortisol synthesis inhibitor. The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. The Company is conducting a Phase III trial of COR-003 for patients with endogenous Cushing's syndrome. The Company's product candidate, COR-005, is a somatostatin analog (SSA). The Company is investigating COR-005 for the treatment of acromegaly, with additional applications in Cushing's syndrome and neuroendocrine tumors. COR-005 is being optimized for sustained release and subcutaneous delivery. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
Strongbridge Biopharma plc
900 Northbrook Dr Ste 200
TREVOSE PA 19053-8433